AbbVie (ABBV) looks to new drugs to boost sales following Humira competition - WSJ

Go back to AbbVie (ABBV) looks to new drugs to boost sales following Humira competition - WSJ

Dell rises premarket; Tyson Foods, Nordstrom fall

February 6, 2023 8:33 AM EST

By Peter Nurse

Investing.com -- Stocks in focus in premarket trade on Monday, February 6th. Please refresh for updates.

Dell Technologies (NYSE: DELL) stock rose 1.5% after Bloomberg reported that the tech company was planning on slashing around 6,650 jobs, or about 5% of its global... More

AbbVie (ABBV) looks to new drugs to replace Humiria, lifts deal limit - WSJ

February 6, 2023 7:05 AM EST

AbbVie (NYSE: ABBV) is looking to two newer immune drugs to offset Humira generic competition and is lifting a self-imposed $2 billion limit on the size of potential deals it could be targeting, the Wall Street Journal reported

... More

Abbvie (ABBV) PT Lowered to $167 at BMO Capital

February 6, 2023 6:39 AM EST

BMO Capital analyst Gary Nachman lowered the price target on Abbvie (NYSE: ABBV) to $167.00 (from $169.00) while maintaining a Outperform rating.... More

Abbvie plans to lift $2 billion cap on deals - WSJ

February 6, 2023 6:35 AM EST

(Reuters) - Abbvie will lift a self-imposed $2 billion limit on acquisitions and mergers placed following a $63 billion deal for Botox maker Allergan in 2020 that shot up its debt, the company's chief executive officer told the Wall Street Journal.

Chief Executive Officer Richard Gonzalez said the company now has the... More